Harvard Bioscience, Inc.HBIONASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-2.60%
↓ 245% below average
Average (39q)
1.79%
Historical baseline
Range
High:57.40%
Low:-23.82%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -2.60% |
| Q2 2025 | -5.69% |
| Q1 2025 | -0.30% |
| Q4 2024 | -9.31% |
| Q3 2024 | -2.25% |
| Q2 2024 | -8.98% |
| Q1 2024 | -8.41% |
| Q4 2023 | 14.13% |
| Q3 2023 | -6.66% |
| Q2 2023 | 2.07% |
| Q1 2023 | 1.68% |
| Q4 2022 | 3.11% |
| Q3 2022 | -20.99% |
| Q2 2022 | 8.60% |
| Q1 2022 | 9.12% |
| Q4 2021 | 10.94% |
| Q3 2021 | -1.52% |
| Q2 2021 | 8.60% |
| Q1 2021 | 5.87% |
| Q4 2020 | 20.52% |
| Q3 2020 | 2.74% |
| Q2 2020 | -23.82% |
| Q1 2020 | -5.86% |
| Q4 2019 | 3.16% |
| Q3 2019 | -7.47% |
| Q2 2019 | 1.32% |
| Q1 2019 | -10.18% |
| Q4 2018 | 9.41% |
| Q3 2018 | 0.91% |
| Q2 2018 | 14.82% |
| Q1 2018 | 57.40% |
| Q4 2017 | -0.78% |
| Q3 2017 | 18.67% |
| Q2 2017 | 0.86% |
| Q1 2017 | 11.16% |
| Q4 2016 | -11.69% |
| Q3 2016 | -12.85% |
| Q2 2016 | 5.40% |
| Q1 2016 | -6.98% |
| Q4 2015 | 7.43% |